Search Results - "Illidge, T.M"

British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous lymphomas 2018 by Gilson, D., Whittaker, S.J., Child, F.J., Scarisbrick, J.J., Illidge, T.M., Parry, E.J., Mohd Mustapa, M.F., Exton, L.S., Kanfer, E., Rezvani, K., Dearden, C.E., Morris, S.L.

“…Linked Editorial: Wang and Bagot. Br J Dermatol 2019; 180:443–444…”
Get full text

Emerging Opportunities for the Combination of Molecularly Targeted Drugs with Radiotherapy by Searle, E.J, Illidge, T.M, Stratford, I.J

“…Abstract Recent drug discovery developments in the field of small molecule targeted agents have led to much interest in combining these with radiotherapy…”
Get full text

Validation of an ELISA for the determination of rituximab pharmacokinetics in clinical trials subjects by Hampson, G., Ward, T.H., Cummings, J., Bayne, M., Tutt, A.L., Cragg, M.S., Dive, C., Illidge, T.M.

“…Rituximab is a chimeric anti-CD20 monoclonal antibody that has revolutionised the treatment of many B-cell malignancies, and is now increasingly being used in…”
Get full text

Methodological Considerations in the Evaluation of Radiotherapy Technologies by Burnet, N.G, Billingham, L.J, Chan, C.S.K, Hall, E, Macdougall, J, Mackay, R.I, Maughan, T.S, Nutting, C.M, Staffurth, J.N, Illidge, T.M

Get full text

Radiotherapy Research Priorities for the UK by Maughan, T.S, Illidge, T.M, Hoskin, P, McKenna, W.G, Brunner, T.B, Stratford, I.J, Harrington, K.J, Plummer, R, Billingham, L.J, Nutting, C, Burnet, N.G, Mackay, R.I, Oliver, A, Young, C, Chan, C.S.K

Get full text

Immunogenic Effects of Radiotherapy for Bladder Cancer by Walshaw, R.C., Roberts, J., Swan, J., Honeychurch, J., Choudhury, A., Illidge, T.M.

Get full text

Recommendations for the clinical management of the elderly patient with malignant lymphoma by Specht, L., Aleman, B., Eich, H., Illidge, T.M., Kirova, Y., Mikhaeel, N.G., Ricardi, U., Yahalom, J.

Get full text

Final results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous t-cell lymphomas (CTCL) (Mycosis fungoides and Sézary syndrome) by Dummer, R., Duvic, M., Scarisbrick, J., Olsen, E.A., Rozati, S., Eggmann, N., Goldinger, S.M., Hutchinson, K., Geskin, L., Illidge, T.M., Giuliano, E., Elder, J., Kim, Y.H.

“…Forodesine is a potent inhibitor of purine nucleoside phosphorylase (PNP) that leads to intracellular accumulation of deoxyguanosine triphosphate (dGTP) in T…”
Get full text

CLINICAL OUTCOMES ASSOCIATED WITH THE TREATMENT OF NEWLY DIAGNOSED STAGE IV CLASSICAL HODGKIN LYMPHOMA IN PRACTICE SETTINGS IN FRANCE, GERMANY AND THE UNITED KINGDOM by Dalal, M.R., Hentrich, M.U., Stamatoullas‐Bastard, A., Zagadailov, E.A., Gautam, A., Way, N.A., Cambron‐Mellott, M., Illidge, T.M.

Get full text

Segregation of genomes in polyploid tumour cells following mitotic catastrophe by Erenpreisa, Jekaterina, Kalejs, M., Ianzini, F., Kosmacek, E.A., Mackey, M.A., Emzinsh, D., Cragg, M.S., Ivanov, A., Illidge, T.M.

“…Following irradiation p53-function-deficient tumour cells undergo mitotic catastrophe and form endopolyploid cells. A small proportion of these segregates…”
Get full text

A21 The microscopic tumour biodistribution of 131I-labelled mAb is critical in predicting successful radioimmunotherapy of lymphoma by Du, Y., Glennie, M.J., Johnson, P.W., Illidge, T.M.

Get full text

A50 iodogen labelling method preserves immunoreactivity of high specific activity 131I-labelled rituximab for clinical RIT by Du, Y., Bayne, M., Zivanovic, M., Johnson, P.W., Illidge, T.M.

Get full text

A41 PHASE I/II STUDY OF FRACTIONATED RADIOIMMUNOTHERAPY IN RELAPSED LOW GRADE NON-HODGKIN??S LYMPHOMA by Zivanovic, M.A., Bayne, M., Du, Y., Illidge, T.M., Lewington, V.J.

Get full text

A20 Phase I/II study of fractionated radioimmunotherapy in relapsed low grade non-Hodgkin??s lymphoma by Zivanovic, M.A., Bayne, M.C., Illidge, T.M., Du, Y., Lewington, V.J., Johnson, P.W.

Get full text

What's new in the management of cutaneous T-cell lymphoma? by McFarlane, V., Friedmann, P.S., Illidge, T.M.

“…The aetiology and clinical management of primary cutaneous T-cell lymphoma (CTCL) and specifically of mycosis fungoides and Sezary syndrome are poorly defined…”
Get full text

Hypercalcaemia, Parathyroid Hormone-Related Protein and Malignancy by Bayne, M.C., Illidge, T.M.

“…Hypercalcaemia is the most common serious metabolic complication of malignancy. Recent advances have significantly increased our understanding of the…”
Get full text

Trastuzumab: Designer Drug or Fashionable Fad? by Freebairn, A.J.E., Last, A.T.J., Illidge, T.M.

“…Trastuzumab (Herceptin) is the first monoclonal antibody to be approved for the treatment of a solid tumour and is directed against the c-erb-B2 receptor. c-…”
Get full text

Cervical Neuropathy Following Mantle Radiotherapy by McFarlane, V.J., Clein, G.P., Cole, J., Cowley, N., Illidge, T.M.

“…The majority of newly diagnosed patients with Hodgkin's lymphoma are expected to survive because of effective therapies established during the last 40 years…”
Get full text

The Junior Radiology Forum: What do the trainees think about the future of oncology training? by Illidge, T.M.

Get full text

Malignant hypercalcaemia in pregnancy and antenatal administration of intravenous pamidronate by Illidge, T.M., Hussey, M., Godden, C.W.

“…A patient is reported who was found to have metastatic breast cancer in pregnancy. Intravenous pamidronate was given with beneficial effect in the third…”
Get full text